Rein Therapeutics Stock Forecast

RNTX's stock price has decreased by -61.44% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Rein Therapeutics stock has a target of 10, which predicts a 545.16% increase from the current stock price of 1.55.

Price Target: $10 (+545.16%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$10	$10	$10	$10
Change	+545.16%	+545.16%	+545.16%	+545.16%

* Price targets were last updated on Sep 22, 2025.

Analyst Ratings

The average analyst rating for Rein Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25
Strong Buy	0	1	1
Buy	0	0	0
Hold	1	1	1
Sell	0	0	0
Strong Sell	0	0	0
Total	1	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brandon Folkes HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $10	Strong Buy	Initiates	$10	+545.16%	Sep 22, 2025
Kemp Dolliver Brookline Capital	Brookline Capital	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Aug 19, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.98

from -3.51

EPS Next Year

-0.83

from -0.98

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-12.14	-5.89	-6.02	-3.42	-3.51	-0.98	-0.83
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	4	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2025	2026
High	-0.97	-0.85
Avg	-0.98	-0.83
Low	-0.99	-0.79

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.